Hebei Changshan Biochemical Hits Day Low at CNY 25.06 Amid Price Pressure

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.8% on July 13, 2026. The stock reached an intraday low of CNY 25.06, reflecting ongoing challenges within the company. Over the past month, the stock has seen a significant decrease of 28.19%, while its year-to-date performance shows a steep decline of 59.19%. In comparison, the China Shanghai Composite index has performed better, with a 1-year return of 11.5% and a year-to-date return of -1.39%. The company's long-term fundamentals appear weak, with a return on capital employed (ROCE) of just 3.59%. Additionally, Hebei Changshan has reported negative results for the last four consecutive quarters, with a net profit of CNY -322.94 million, reflecting a decline of 62.45%. Despite being net-debt free, the company has struggled with poor sales growth, evidenced by a 10.97% decrease in net sales over the first half of the year. As a large-cap player in the pharmaceuticals and biotechnology sector, Hebei Changshan continues to face significant market pressures.